Skip to main content
. Author manuscript; available in PMC: 2013 Jul 8.
Published in final edited form as: Ann Surg Oncol. 2008 May 21;15(8):2137–2145. doi: 10.1245/s10434-008-9967-1

TABLE 6.

Peritoneal and plasma oxaliplatin exposure during IPHC

200 mg/M2 250 mg/M2 P-value
0–60 min
 AUCperitoneal fluid (mg/L h) 30.9 ± 5.69 39.1 ± 6.2 0.09
 AUCplasma (mg/L h) 1.5 ± 0.54 1.9 ± 0.5 0.16
 AUCperitoneal fluid/plasma 20.0 ± 6.6 21.5 ± 3.1 0.76
60–120 min
 AUCperitoneal fluid (mg/L h) 18.6 ± 4.1 23.4 ± 3.9 0.09
 AUCplasma (mg/L h) 124.2 ± 42.5 180.7 ± 6.3 0.22
 AUCperitoneal fluid/plasma 9.1 ± 3.9 7.8 ± 1.6 0.99
0–120 min
 AUCperitoneal fluid (mg/L h) 49.6 ± 8.6 62.7 ± 10.2 0.036
 AUCplasma (mg/L h) 3.6 ± 1.2 4.9 ± 0.54 0.036
 AUCperitoneal fluid/plasma 13.7 ± 4.7 12.8 ± 3.1 0.99

AUC, area under the curve.

Values are expressed as the mean±standard deviation.